Stigler Kimberly A, McDougle Christopher J
Department of Psychiatry, Indiana University School of Medicine, Riley Hospital for Children, Room 4300, 702 Barnhill Drive, Indianapolis, IN 46202-5200, USA.
Child Adolesc Psychiatr Clin N Am. 2008 Oct;17(4):739-52, vii-viii. doi: 10.1016/j.chc.2008.06.002.
Children and adolescents diagnosed with autism and related pervasive developmental disorders (PDDs) often sustain irritability, including aggression, self-injurious behavior, and tantrums. Research to date supports the use of the atypical antipsychotics as a first-line pharmacologic treatment for this target symptom domain in PDDs. Currently, the atypical antipsychotic risperidone is the only medication approved by the US Food and Drug Administration for irritability in youth with autism. Additional large-scale, placebo-controlled studies of other medications are needed to determine their efficacy for the treatment of irritability in this diagnostic group.
被诊断患有自闭症及相关广泛性发育障碍（PDDs）的儿童和青少年常常会出现易怒情绪，包括攻击行为、自伤行为和发脾气。迄今为止的研究支持将非典型抗精神病药物作为治疗PDDs中这一目标症状领域的一线药物治疗方法。目前，非典型抗精神病药物利培酮是美国食品药品监督管理局批准用于治疗自闭症青少年易怒情绪的唯一药物。还需要对其他药物进行更多大规模、安慰剂对照研究，以确定它们对该诊断组易怒情绪的治疗效果。
